A Phase 3, Randomized, Double-Blind, Placebo-Controlled

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
StatusActive
Effective start/end date10/1/179/30/21

Funding

  • PTC Therapeutics, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.